

EQA round: AP1/23 - Antithrombotic Agents

Deadline: 31.3.2023

Setup: groups - measurement principle; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL					
Set 1																
(108) Apixaban	[µg/L]				39									39	37	95
Sample A1		63,9	9	14	39		CVP	63,9	3,6	25%	47,9	79,9		39	37	95
(2) Chromogenous substrat		63,6	9,1	14	37	1								37		
Other					2	0								2		
							2x 1									
Sample B1		281	20	7,2	39		CVP	281	8	25%	210	352		39	38	97
(2) Chromogenous substrat		280	20	7,3	37	1								37		
Other					2	0								2		
							2x 1									
Set 2																
(109) Dabigatran	[µg/L]				36									36	34	94
Sample A2		48,3	4,4	9,2	36		CVP	48,3	1,8	30%	33,8	62,8		36	34	94
(1) Coagulometer		48,7	3,9	8	26	0								26		
(2) Chromogenous substrat		47	4,4	9,5	10	1								10		
Sample B2		215	22	10	36		CVP	215	9	30%	150	280		36	35	97
(1) Coagulometer		221	24	11	26	0								26		
(2) Chromogenous substrat		204	14	6,9	10	1								10		
Set 3																
(110) Rivaroxaban	[µg/L]				45									45	44	98
Sample A3		80,1	6	7,4	45		CVP	80,1	2,2	25%	60	101		45	44	98
(2) Chromogenous substrat		79,9	5,8	7,2	43	1								43		
Other					2	0								2		
							2x 1									
Sample B3		292	27	9,1	45		CVP	292	9,8	25%	219	365		45	44	98
(2) Chromogenous substrat		292	26	9	43	1								43		
Other					2	0								2		
							2x 1									